Synucleinopathy refers to a class of neurodegenerative disorders characterized by the abnormal accumulation of alpha-synuclein protein in neurons, glia, or both[1]. These protein aggregates form the pathological hallmark of several movement disorders and dementias, including Parkinson's disease (PD), Dementia with Lewy Bodies (DLB), and Multiple System Atrophy (MSA)[2]. The term encompasses a spectrum of diseases unified by the presence of α-synuclein pathology, each with distinct clinical and pathological features[3].
The synucleinopathies represent a major challenge in neurology, affecting millions of individuals worldwide. Recent epidemiological studies estimate that Parkinson's disease alone affects approximately 1-2% of the population over 65 years of age, rising to 3-5% by age 85[4]. Dementia with Lewy Bodies accounts for 10-15% of all dementia cases, making it the second most common neurodegenerative dementia after Alzheimer's disease[5]. Multiple System Atrophy, while rarer, has a prevalence of approximately 4-5 per 100,000, with a mean survival of 6-10 years from symptom onset[6].
Understanding the common mechanisms underlying α-synuclein aggregation and the factors that determine disease-specific phenotypes is essential for developing effective therapies. Despite sharing a common protein pathology, these diseases exhibit remarkable clinical heterogeneity, reflecting differences in α-synuclein strain properties, cellular distribution, and interaction with other pathological processes.
The global burden of synucleinopathies has been increasingly recognized as populations age worldwide. Parkinson's disease affects approximately 10 million people globally, with incidence rates varying from 5 to 21 per 100,000 person-years depending on geographic region and methodological approach[4:1][7]. The prevalence of PD increases exponentially with age, doubling every 5 years after age 50, reaching nearly 3% in those over 80 years[8]. Notably, men are affected approximately 1.5 times more frequently than women, though this sex difference diminishes in older age groups[9].
Dementia with Lewy Bodies demonstrates a prevalence of 0.3-0.7% in population-based studies, rising to 5-10% in memory clinic settings[10]. The economic burden is substantial, with annual costs in the United States alone exceeding $50 billion for PD management and care[11]. DLB imposes particularly high care costs due to the combination of cognitive impairment, psychiatric symptoms, and motor dysfunction[12].
Multiple System Atrophy has an estimated prevalence of 3.4-4.9 per 100,000, with annual incidence rates of 0.6-0.7 per 100,000[6:1]. The disease typically presents in the fifth to seventh decade of life, with no significant sex predominance. Importantly, MSA demonstrates the most rapid progression among synucleinopathies, with median survival of 6-9 years from diagnosis[13].
The geographic clustering of certain synucleinopathies has been documented, with notably high rates of parkinsonism and dementia observed in Guam, the Kii Peninsula of Japan, and certain regions of Western Pacific islands[14]. These endemic foci have provided important insights into potential environmental and genetic factors contributing to disease pathogenesis.
| Gene | Variant | Effect | Disease Association |
|---|---|---|---|
| SNCA | Multiplication | Increased α-syn expression | PD, DLB |
| SNCA | A53T, E46K, H50Q, G51D | Enhanced aggregation | PD, MSA |
| SNCA | Rep1 promoter polymorphism | Altered expression | PD |
| LRRK2 | G2019S kinase activation | Enhanced aggregation susceptibility | PD |
| GBA | Loss-of-function | Lysosomal dysfunction | PD, DLB |
| ATP13A2 | Loss-of-function | Lysosomal dysfunction | PD, Kufor-Rakeb |
| MAPT | H1 haplotype | Altered tau expression | PD, PSP |
| GBA | N370S, L444P | Severe enzyme deficiency | PD, DLB |
| VPS13C | Loss-of-function | Mitophagy impairment | PD |
The discovery of SNCA gene multiplications in familial PD provided the first direct evidence that increased α-syn expression is sufficient to cause disease[15]. This has profound implications for therapeutic strategies targeting expression reduction. Subsequent identification of pathogenic mutations including A53T, E46K, and H50Q confirmed the central role of α-syn aggregation in disease pathogenesis[16].
Heterozygous GBA mutations represent the most common genetic risk factor for both PD and DLB, increasing disease risk by 5-10 fold in carriers[17]. GBA encodes glucocerebrosidase, a lysosomal enzyme deficiency of which leads to Gaucher disease. The mechanism by which GBA mutations increase synucleinopathy risk involves impaired lysosomal function and accelerated α-syn aggregation[18].
Epidemiological studies have identified several environmental risk factors for synucleinopathies, though definitive causation remains elusive[19]:
Pesticide Exposure: Agricultural workers exposed to pesticides demonstrate a 2-3 fold increased risk of PD, with particular associations for rural living, well water consumption, and specific chemical classes including paraquat, rotenone, and organophosphates[20].
Traumatic Brain Injury: Moderate to severe traumatic brain injury is associated with a 1.5-2.0 fold increased risk of PD, potentially through mechanisms involving blood-brain barrier disruption, neuroinflammation, and direct neuronal injury[21].
Heavy Metals: Chronic exposure to manganese (manganism), lead, and mercury has been linked to parkinsonian syndromes, though the relationship with classic synucleinopathies remains complex[22].
Infections: Historical studies suggested associations between influenza, herpes simplex virus, and PD risk, though recent evidence regarding COVID-19 and long-term neurological outcomes continues to emerge[23].
Protective Factors: Caffeine consumption, smoking (though confounded by latency effects), physical activity, and Mediterranean diet adherence have been associated with reduced PD risk[24].
Alpha-synuclein (α-syn is a 140-amino acid protein encoded by the SNCA gene, primarily expressed in presynaptic terminals[25]. The protein is composed of three distinct domains:
N-terminal Domain (residues 1-60): Contains seven imperfect repeats of the sequence KTKEGV, which mediate lipid binding and are critical for the protein's α-helical structure when associated with membranes[26]. Pathogenic mutations in this region (A30P, E46K, H50Q, G51D, A53T) alter the membrane binding properties and increase aggregation propensity.
Central Aggregation-Prone Domain (residues 61-95): This region contains the NAC (non-Aβ component) subsequence, which is essential for β-sheet formation and fibril assembly[27]. The hydrophobic nature of this domain drives protein-protein interactions that lead to oligomerization.
C-terminal Domain (residues 96-140): Acidic and proline-rich, this domain exerts an anti-aggregating effect under normal physiological conditions[28]. The C-terminus also serves as a binding site for various molecular chaperones and metal ions (Cu²⁺, Fe³⁺).
Under normal conditions, α-syn exists as a natively unfolded monomer that can form helical multimers upon membrane association. The protein is involved in synaptic vesicle trafficking, neurotransmitter release regulation, and neuronal plasticity[29].
Under pathological conditions, α-syn undergoes a series of conformational changes[30]:
The aggregation process is influenced by multiple factors including post-translational modifications (phosphorylation, ubiquitination, nitration), metal ion binding, cellular stress, and genetic variants. Phosphorylation at Ser129 is the most common modification found in pathological inclusions, present in over 90% of Lewy body pathology[31].
Post-Translational Modifications:
The table above outlines the major genetic contributors to synucleinopathy risk. Pathogenic variants in SNCA demonstrate autosomally dominant inheritance with high penetrance, while risk variants in genes like GBA and LRRK2 exert their effects through altered protein function rather than complete loss[36].
In Parkinson's disease, α-syn aggregates primarily in Lewy bodies (intracellular inclusions) and Lewy neurites (neuronal processes)[37]. Lewy bodies are spherical, eosinophilic inclusions composed of a dense core surrounded by a halo of filamentous material. The core consists of packed α-syn fibrils, while the halo contains smaller oligomeric species and associated proteins including p62, ubiquitin, and Parkin[38].
The progression follows a staging system originally described by Braak and colleagues:
Braak staging:
This staging pattern suggests a prion-like propagation from the periphery and lower brainstem upward to the cortex[39]. The Olfactory bulb is often affected early, explaining the common onset of hyposmia (loss of smell) in prodromal PD.
Clinical Correlation:
The progression is not uniform across all patients. Some individuals present with Tremor-dominant PD, while others show Postural Instability/Gait Difficulty (PIGD) phenotypes, each with different rates of progression and non-motor symptom profiles[40].
Clinical Subtypes:
In Dementia with Lewy Bodies, α-syn pathology is more diffuse and predominantly affects cortical regions[42]:
Pathological Features:
Clinical Features (core diagnostic criteria):
The presence of visual hallucinations is a key distinguishing feature from Alzheimer's disease and is thought to reflect the impact of α-syn pathology on visual processing pathways and cholinergic dysfunction[43].
Diagnostic Criteria Updates:
The 2017 consensus criteria introduced "indicative biomarkers" that enhance diagnostic accuracy:
In Multiple System Atrophy, α-syn forms glial cytoplasmic inclusions (GCIs) in oligodendrocytes, the myelin-producing cells of the central nervous system[45]:
Pathological Features:
Clinical Features:
The predominance of oligodendrocyte pathology in MSA is remarkable and suggests that the cellular distribution of α-syn aggregates fundamentally determines the clinical phenotype. This has led to hypotheses about strain-specific properties of α-syn in MSA[46].
Clinical Variants:
Parkinsonism-Dementia Complex of Guam: An endemic disorder with features of parkinsonism and dementia associated with ALS-like syndrome, now known to involve α-syn pathology[48].
Pure Autonomic Failure: Characterized by α-syn accumulation in peripheral autonomic neurons, often representing an early or forme fruste of synucleinopathy[49].
Dementia with Braak Stage: Some cases show limbic-predominant age-related transactive response DNA-binding protein-43 (TDP-43) pathology with Lewy bodies[50].
Incidental Lewy Body Disease: Approximately 5-10% of neurologically normal individuals over age 60 demonstrate Lewy body pathology at autopsy, representing prodromal or pre-clinical stages of synucleinopathy[51].
α-Synuclein oligomers impair mitochondrial function through multiple mechanisms[52]:
Complex I Inhibition: Direct interaction with mitochondrial respiratory chain[53]:
The finding of Complex I deficiency in substantia nigra of PD patients predated the discovery of α-syn pathology and is now recognized as a consequence of α-syn accumulation[54].
Dynamics Alteration: Effects on mitochondrial fusion and fission[55]:
α-Syn localizes to mitochondria in both PD models and patient brains, where it directly inhibits mitochondrial Complex I activity and promotes mitochondrial fragmentation[56].
Mitochondrial DNA Damage: α-Syn accumulation is associated with increased mitochondrial DNA deletions and reduced mitochondrial DNA copy number in substantia nigra neurons[57].
The autophagy-lysosome pathway is critically impaired in synucleinopathies[58]:
Reduced GBA Activity: Glucocerebrosidase (GBC) deficiency, whether due to GBA gene mutations or sporadic dysfunction, accelerates aggregation[59]:
Heterozygous GBA mutations are the most common genetic risk factor for both PD and DLB, increasing risk by 5-10 fold in carriers[17:1].
Autophagy Types Affected:
α-Syn activates glial cells, creating a self-perpetuating inflammatory loop[60]:
Microglial Activation: Via TLR2/TLR4 recognition[61]:
Astrocytic Involvement: Reactive astrocyte responses[62]:
ER stress is a consistent finding in synucleinopathy models and patient tissue[63]:
The ER and mitochondria form close contacts (mitochondria-associated ER membranes, MAM), and disruption of this axis contributes to both calcium dysregulation and mitochondrial dysfunction[64].
One of the most important conceptual advances in synucleinopathy research has been the recognition that pathological α-syn can propagate in a prion-like manner[65]:
Cell-to-Cell Transmission:
Strain Diversity:
Olfactory Route: The olfactory bulb receives input from the nasal cavity and may represent an entry point for environmental toxins or pathogens that trigger α-syn pathology[67].
Vagal Route: α-Syn pathology progresses along the vagus nerve from the gastrointestinal system to the dorsal motor nucleus, explaining the common prodromal gastrointestinal symptoms in PD[68].
Trans-synaptic Spread: Following anatomically connected pathways, α-syn seeds travel trans-synaptically to connected brain regions[69].
The development of accurate animal models has been crucial for understanding synucleinopathy pathogenesis and testing therapeutic interventions[70]:
Toxic Models:
Genetic Models:
Limitations:
Parkinson's Disease: UK Brain Bank Criteria require bradykinesia plus at least one additional feature (resting tremor, rigidity, or postural instability)[77].
Dementia with Lewy Bodies:
Multiple System Atrophy:
Cerebrospinal Fluid:
Neuroimaging:
Skin Biopsy: Phospho-α-syn detection in cutaneous nerve fibers provides high diagnostic accuracy[85].
Emerging Biomarkers:
Motor Symptoms (PD):
Motor Symptoms (MSA): Limited response to levodopa; may try high doses; supportive measures.
Non-Motor Symptoms:
Immunotherapies:
Aggregation Inhibitors:
Gene Therapy:
Cell Replacement:
Multiple disease-modifying approaches are currently in various stages of clinical development[96]:
Phase 3 Trials:
Phase 2 Trials:
Phase 1 Trials:
The therapeutic landscape for synucleinopathies spans symptomatic management and disease-modifying strategies, with multiple modalities currently in development[@therapeutic2023]. The challenge lies in targeting the underlying α-syn aggregation while addressing the diverse clinical manifestations across PD, DLB, and MSA.
Symptomatic Approaches:
Disease-Modifying Strategies:
Early and accurate diagnosis remains challenging, but several biomarker approaches show promise[103]:
Fluid Biomarkers:
Imaging Biomarkers:
Clinical Biomarkers:
Multiple trials are investigating disease-modifying therapies for synucleinopathies[@trials2025]:
| Agent | Type | Phase | Status | Indication |
|---|---|---|---|---|
| Prasinezumab | Anti-α-syn antibody | Phase 2 | Completed | PD |
| Cinpanemab | Anti-α-syn antibody | Phase 2 | Discontinued | PD |
| ACI-7104 | Active vaccine | Phase 1/2 | Recruiting | PD |
| UD101 | Active vaccine | Phase 2 | Recruiting | PD |
| Anle138b | Aggregation inhibitor | Phase 1 | Completed | PD |
| Ambroxol | GBA modulator | Phase 2 | Ongoing | PD/DLB |
Key Challenges in Trial Design:
Synucleinopathies profoundly affect quality of life across multiple domains:
Motor Symptoms (PD):
Non-Motor Symptoms:
Disease Progression:
Key Challenges:
Emerging Directions:
The translation of basic science discoveries into effective therapies requires careful patient selection, validated biomarkers, and innovative trial designs that account for the heterogeneity inherent in synucleinopathies.
The field of synucleinopathy research is rapidly evolving, with several promising avenues for future investigation and therapeutic development[104]:
Strain-Specific Therapies: Understanding the structural basis of α-syn strain diversity may enable personalized approaches targeting specific conformations associated with individual diseases[105].
Biomarker Development: Early and accurate diagnosis remains challenging; development of validated biomarkers for prodromal stages is essential for preventive interventions[103:1].
Combination Therapies: Given the multi-factorial nature of synucleinopathies, combination approaches targeting aggregation, propagation, neuroinflammation, and cellular dysfunction may prove most effective[106].
Precision Medicine: Genetic stratification using variants in SNCA, GBA, LRRK2, and other risk genes may guide therapy selection and enable personalized treatment approaches[107].
Synucleinopathies represent a spectrum of diseases unified by α-synuclein pathology. Understanding strain diversity, propagation mechanisms, and disease-specific factors is essential for developing targeted therapies. The recognition of prion-like propagation has fundamentally changed our therapeutic approach, shifting focus from neuroprotection to preventing the spread of pathology. Advances in biomarker development enable earlier diagnosis and monitoring of disease progression, while multiple disease-modifying approaches are in clinical development, offering hope for these devastating disorders.
The convergence of genetic, pathological, and clinical research has illuminated the complex interplay between α-syn aggregation, cellular dysfunction, and network degeneration. Future success will require continued integration of basic science discoveries with clinical translation, international collaboration, and patient-centered approaches to developing effective therapies for these progressive and debilitating conditions.
Synucleinopathies - Nature Reviews Neurology. Nature Reviews Neurology. 2020. ↩︎
Classification - Lancet Neurology. Lancet Neurology. 2019. ↩︎
Spectrum - Brain. Brain. 2018. ↩︎
PD Epidemiology - Lancet Neurology. Lancet Neurology. 2014. ↩︎ ↩︎
DLB Prevalence - Neurology. Neurology. 2005. ↩︎
MSA Prevalence - Movement Disorders. Movement Disorders. 2005. ↩︎ ↩︎
Global PD Burden - Movement Disorders. Movement Disorders. 2015. ↩︎
PD Age Prevalence - Neurology. Neurology. 2003. ↩︎
PD Sex Differences - Neurology. Neurology. 2010. ↩︎
DLB Epidemiology - Current Opinion in Neurology. Current Opinion in Neurology. 2018. ↩︎
PD Economic Burden - Movement Disorders. Movement Disorders. 2016. ↩︎
DLB Cost - Alzheimer's & Dementia. Alzheimer's & Dementia. 2020. ↩︎
MSA Survival - Brain. Brain. 2010. ↩︎
Guam PD - Neurology. Neurology. 2006. ↩︎
SNCA Triplication - Science. Science. 2004. ↩︎
SNCA Mutations - Brain. Brain. 2015. ↩︎
GBA Risk - Lancet Neurology. Lancet Neurology. 2011. ↩︎ ↩︎
GBA Mechanism - Nature Reviews Neurology. Nature Reviews Neurology. 2017. ↩︎
PD Risk Factors - Current Neurology and Neuroscience Reports. Current Neurology and Neuroscience Reports. 2019. ↩︎
Pesticides PD - Environmental Health Perspectives. Environmental Health Perspectives. 2007. ↩︎
TBI PD Risk - Neurology. Neurology. 2012. ↩︎
Metals PD - Toxicological Research. Toxicological Research. 2017. ↩︎
Infection PD - Journal of Parkinson's Disease. Journal of Parkinson's Disease. 2021. ↩︎
Protective Factors - Journal of Parkinson's Disease. Journal of Parkinson's Disease. 2019. ↩︎
SNCA - Nature Reviews Neuroscience. Nature Reviews Neuroscience. 2021. ↩︎
α-Syn Membrane Binding - Journal of Molecular Biology. Journal of Molecular Biology. 2001. ↩︎
NAC Domain - Journal of Biological Chemistry. Journal of Biological Chemistry. 1994. ↩︎
C-terminal Domain - Journal of Molecular Biology. Journal of Molecular Biology. 2011. ↩︎
Synaptic Function - Nature Reviews Neuroscience. Nature Reviews Neuroscience. 2009. ↩︎
Aggregation - Nature Reviews Molecular Cell Biology. Nature Reviews Molecular Cell Biology. 2020. ↩︎
Ser129 Phosphorylation - Journal of Neuropathology & Experimental Neurology. Journal of Neuropathology & Experimental Neurology. 2003. ↩︎
Ser129 Phosphorylation Mechanism - Journal of Biological Chemistry. Journal of Biological Chemistry. 2013. ↩︎
α-Syn Ubiquitination - Nature Neuroscience. Nature Neuroscience. 2000. ↩︎
Nitration - Journal of Neurochemistry. Journal of Neurochemistry. 2006. ↩︎
Sumoylation - Journal of Biological Chemistry. Journal of Biological Chemistry. 2011. ↩︎
Genetic Architecture - Neuron. Neuron. 2021. ↩︎
Lewy bodies - Brain. Brain. 2003. ↩︎
Lewy Body Composition - Acta Neuropathologica. Acta Neuropathologica. 2012. ↩︎
Braak Staging - Neurobiology of Aging. Neurobiology of Aging. 2003. ↩︎
PD Phenotypes - Brain. Brain. 2009. ↩︎
PD Subtypes - Movement Disorders. Movement Disorders. 2009. ↩︎
DLB pathology - Brain. Brain. 2005. ↩︎
DLB Visual Hallucinations - Brain. Brain. 2009. ↩︎
DLB criteria - Neurology. Neurology. 2017. ↩︎ ↩︎
MSA - Nature Reviews Neurology. Nature Reviews Neurology. 2010. ↩︎
MSA Strains - Nature Neuroscience. Nature Neuroscience. 2016. ↩︎
MSA Clinical Variants - Movement Disorders. Movement Disorders. 2005. ↩︎
Guam PDC - Journal of Neural Transmission. Journal of Neural Transmission. 2012. ↩︎
Pure Autonomic Failure - Neurology. Neurology. 2015. ↩︎
Limbic-predominant TDP-43 - Brain. Brain. 2018. ↩︎
Incidental LBD - Journal of Neuropathology & Experimental Neurology. Journal of Neuropathology & Experimental Neurology. 1998. ↩︎
Mitochondrial dysfunction - Journal of Bioenergetics and Biomembranes. Journal of Bioenergetics and Biomembranes. 2009. ↩︎
Complex I - Nature Reviews Neuroscience. Nature Reviews Neuroscience. 2009. ↩︎
Complex I Deficiency - Journal of Neurochemistry. Journal of Neurochemistry. 2000. ↩︎
Dynamics - Nature Reviews Molecular Cell Biology. Nature Reviews Molecular Cell Biology. 2009. ↩︎
α-Syn Mitochondria - Journal of Clinical Investigation. Journal of Clinical Investigation. 2011. ↩︎
Mitochondrial DNA - Brain. Brain. 2013. ↩︎
Lysosomal dysfunction - Nature Reviews Neurology. Nature Reviews Neurology. 2010. ↩︎
GBA - Brain. Brain. 2013. ↩︎
Neuroinflammation - Journal of Neuroinflammation. Journal of Neuroinflammation. 2009. ↩︎
Microglia - Glia. Glia. 2009. ↩︎
Astrocytes - Neurobiology of Disease. Neurobiology of Disease. 2012. ↩︎
ER Stress - Cell Death & Disease. Cell Death & Disease. 2013. ↩︎
MAM - Nature Neuroscience. Nature Neuroscience. 2015. ↩︎
Prion-like Propagation - Nature Reviews Neurology. Nature Reviews Neurology. 2015. ↩︎
MSA Strain - Nature Communications. Nature Communications. 2015. ↩︎
Olfactory Route - Acta Neuropathologica. Acta Neuropathologica. 2017. ↩︎
Vagal Route - Nature Reviews Neurology. Nature Reviews Neurology. 2019. ↩︎
Trans-synaptic Spread - Nature Neuroscience. Nature Neuroscience. 2012. ↩︎
Animal Models Review - Neurobiology of Disease. Neurobiology of Disease. 2016. ↩︎
PFF Model - Nature Neuroscience. Nature Neuroscience. 2010. ↩︎
Viral Vector Model - Molecular Therapy. Molecular Therapy. 2017. ↩︎
Transgenic Models - Neuroscience. Neuroscience. 2006. ↩︎
Knock-in Models - Nature Neuroscience. Nature Neuroscience. 2011. ↩︎
Multi-gene Models - Brain. Brain. 2015. ↩︎
Model Limitations - Movement Disorders. Movement Disorders. 2015. ↩︎
UK Brain Bank - Brain. Brain. 1991. ↩︎
MSA criteria - Movement Disorders. Movement Disorders. 2008. ↩︎
RT-QuIC - Annals of Neurology. Annals of Neurology. 2015. ↩︎
Total α-syn - Neurology. Neurology. 2009. ↩︎
Phospho-α-syn - Neurology. Neurology. 2013. ↩︎
NfL - Neurology. Neurology. 2015. ↩︎
DaTSPECT - Movement Disorders. Movement Disorders. 2008. ↩︎
MIBG - Journal of Neurology, Neurosurgery & Psychiatry. Journal of Neurology, Neurosurgery & Psychiatry. 2003. ↩︎
Skin Biopsy - Movement Disorders. Movement Disorders. 2019. ↩︎
Seeding Assays - Acta Neuropathologica. Acta Neuropathologica. 2015. ↩︎
Urinary α-syn - Movement Disorders. Movement Disorders. 2015. ↩︎
Optic Nerve Ultrasound - Movement Disorders. Movement Disorders. 2014. ↩︎
A2A Antagonists - Lancet. Lancet. 2017. ↩︎
Passive immunotherapy - Nature Reviews Neurology. Nature Reviews Neurology. 2019. ↩︎
Active immunotherapy - Movement Disorders. Movement Disorders. 2021. ↩︎
Anle138b - Nature Communications. Nature Communications. 2014. ↩︎
EGCG - Journal of Alzheimer's Disease. Journal of Alzheimer's Disease. 2012. ↩︎
SynuClean-D - Nature Communications. Nature Communications. 2018. ↩︎
Gene Therapy - Molecular Therapy. Molecular Therapy. 2019. ↩︎
Clinical Trials - Nature Reviews Drug Discovery. Nature Reviews Drug Discovery. 2020. ↩︎
Prasinezumab - Movement Disorders. Movement Disorders. 2022. ↩︎
Cinpanemab - Movement Disorders. Movement Disorders. 2021. ↩︎
UD101 - Translational Neurodegeneration. Translational Neurodegeneration. 2022. ↩︎
Sarizotan - Movement Disorders. Movement Disorders. 2020. ↩︎
Gene Therapy Trials - Molecular Therapy. Molecular Therapy. 2019. ↩︎
Small Molecule Inhibitors - Journal of Medicinal Chemistry. Journal of Medicinal Chemistry. 2019. ↩︎
Biomarker Development - Nature Reviews Neurology. Nature Reviews Neurology. 2024. ↩︎ ↩︎
Future Directions - Nature Reviews Neurology. Nature Reviews Neurology. 2022. ↩︎
Strain Therapy - Science. Science. 2023. ↩︎
Combination Therapy - Neurobiology of Disease. Neurobiology of Disease. 2022. ↩︎
Precision Medicine - Brain. Brain. 2023. ↩︎